Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide (Revlimid) maintenance therapy in relapsed or refractory B-cell chronic lymphocytic leukemia
2007-001626-27Phase 3Unknown
- Sponsor
- Celgene Corporation
- Start
- Oct 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) comparing Lenalidomide (Revlimid) maintenance with Placebo maintenance (2 arms). Primary endpoint: Overall survival. Status: unknown.
02
Drugs
lenalidomide
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2007-001626-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001626-27.